Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the molecular response to high dose Gleevec in newly diagnosed
patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase. This study will evaluate
the ability of Gleevec to reduce the amount of abnormal protein that occurs in patients with
CML.
Patients who are eligible to participate will be treated for 18 months. This trial will
include male or female patients 18 years or older who are newly diagnosed (within 6 months)
with CML.